This website is intended for US Healthcare Professionals.

CONTact Your MSL
Back to Congresses

ASCO-GU 2023

  • February 16 -
  • 18, 2023
  •  |
  • San Francisco, CA

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Poster
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)
DP Petrylak et al.
View Material
View Summary

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP